Columbia, MD – March 11, 2020 – Welldoc, a leading digital health company, announced today a collaboration with Dexcom, the global leader in continuous glucose monitoring (CGM) systems for people with diabetes. Welldoc and Dexcom signed an initial data partnership in 2019. This new collaboration will allow Welldoc’s award-winning BlueStar®, a digital health product for individuals living with type 1 and type 2 diabetes, to deliver insights to Dexcom G6® CGM system users. These insights go beyond glucose trends to inform individuals how their glucose is being affected by other key parameters, including medication adherence, activity, nutrition, sleep and more. The parties will also explore additional opportunities with Welldoc customers to leverage a more integrated offering.
“This is a pivotal time for those in digital health to work together to combine our expertise – in the utilization of technology and data science to drive user engagement and clinical outcomes,” said Welldoc CEO Kevin McRaith. “This partnership is a significant milestone for Dexcom, Welldoc, healthcare providers, and most importantly for those living with diabetes. These are the types of collaborations that will move the needle forward in improving population health.”
BlueStar is an FDA-cleared digital health solution for type 1 and type 2 diabetes. It engages people with diabetes and delivers precision feedback to help improve long-term health. In addition to the new collaboration with Dexcom, BlueStar also integrates with blood glucose meters, pharmacies, labs and activity and fitness trackers, to make managing everyday life as simple as possible. On the backend, BlueStar aggregates various dimensions of data to deliver actionable insights to the individual’s own care team, providing new opportunities to optimize care.
“Dexcom is thrilled to integrate our G6 data into the Welldoc BlueStar platform to deliver an actionable digital solution to people with diabetes and their healthcare providers,” said Matt Dolan, general manager of new markets for Dexcom. “Now that users can view Dexcom CGM values alongside many other important data types with BlueStar, we hope people with diabetes can better manage their condition in a way that is both personalized and effective.”
Welldoc®, a founding member of the Digital Therapeutics Alliance, is a pioneer in revolutionizing chronic disease management to help transform lives. BlueStar® was the first FDA-cleared digital health solution that guides individuals through the complicated journey of living with diabetes. By helping individuals with chronic disease self-manage their conditions and connecting them to their own healthcare team, Welldoc streamlines payers, employers and healthcare systems resources by focusing on a digital health solution to help better manage their populations living with multiple and costly chronic diseases. Having conducted multiple randomized clinical trials resulting in 46 peer-reviewed publications, Welldoc is based on a life science model. BlueStar has been recognized by IQVIA in 2017 as the “Top App” for type 2 diabetes treatment, awarded Diabetes Technology Society’s 2019 Digital Diabetes Congress Mobile App Contest in the “Established App” category, and MedTech Breakthrough’s 2019 “Best Personal Health App” award. Welldoc has created a suite of products that apply across a chronic disease domain. In 2019, Welldoc received its 10th patent with 9 others pending. For more information, visit www.welldoc.com.